source
- Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapyA patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup. The death marks the third fatality reported in…
- Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositisArgenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…